A passenger gene with profound clinical consequences.

MTAP doesn't get deleted because tumors gain an advantage from losing it. It gets deleted because it sits roughly 100 kilobases from CDKN2A — one of the most frequently inactivated tumor suppressors in human cancer. When a tumor deletes the CDKN2A locus to escape cell-cycle control, MTAP almost always goes with it.

That co-deletion is what makes MTAP loss so common, and so predictable. Wherever you see homozygous CDKN2A loss on 9p21.3, MTAP is the silent passenger — and the actionable one.

MTAP encodes an enzyme central to the methionine salvage pathway. It converts methylthioadenosine (MTA) — a byproduct of polyamine synthesis — back into methionine and adenine. When the gene is deleted, MTA accumulates inside the cell.

That accumulation is the key. MTA is a potent natural inhibitor of PRMT5, the protein arginine methyltransferase responsible for symmetric dimethylation of arginine residues on histones and splicing factors.

MTAP-deleted cells exist in a state of partial PRMT5 inhibition. They rely on whatever residual PRMT5 activity remains. Selective PRMT5 inhibitors that bind cooperatively with MTA can push these cells past a threshold that healthy, MTAP-intact cells never reach.

The result is a therapeutic window — a vulnerability that exists only in the cells you want to kill.

MTAP-null tumors are uniquely sensitive to PRMT5 inhibition. Wild-type cells, which efficiently clear MTA, are largely spared.

Reported rates vary by assay and cohort. Across most large molecular datasets, homozygous MTAP deletion appears in 10–25% of patients depending on tumor type — a frequency on par with many biomarkers already in routine clinical use.

PRMT5 has been studied as an oncology target for more than a decade, but first-generation inhibitors lacked selectivity. A new wave of MTA-cooperative PRMT5 inhibitors selectively engages the enzyme in MTAP-deleted cells, reopening the therapeutic window.

Several of these agents are now in clinical development. Identifying MTAP status earlier — at diagnosis, not at progression — means patients can be matched to trials while they are still candidates.